Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Early last week, the Nasdaq Composite Index - the bellwether for U.S. tech sector - eclipsed the 5,000 level for the first time in 15 years.
The bears would have you believe this is proof that tech stocks in 2015 are simply surging inside a "bubble" - and that a collapse like the dot-com debacle of 2000 is close at hand.
I'm here to tell you folks that those gloom-and-doomers are wrong.
Over the last two years, I've repeatedly shared my belief that, in the long run, technology shares will beat the broader market - and by a wide margin.
Today I'm going to show you why...
Room to Grow for Tech Stocks in 2015
As a senior advisor to Silicon Valley startups at the time, I had a front-row seat for the dot-com meltdown in 2000.
So when I tell you there simply is no comparison between today's Nasdaq and the go-go years of the Roaring '90s, I speak with authority.
Let's start by comparing the pace of tech investing then and now. This gives us a sense of how the "greed factor" affected stock values in the late 1990s.
Data compiled by market-value experts Birinyi Associates reveals that back in the dot-com era it took the Nasdaq just 49 days to rise from 4,000 to 5,000, a climb of 25%.
This time around, using the Birinyi standard, it has taken nine times as long - or 455 days - to do the same thing.
You can look this up yourself. The Nasdaq closed at 4,017 on Nov. 26, 2013, and closed at 5,008 on March 2.
And despite a much larger economy and 15 years of inflation since then, 2015 tech stocks are substantially cheaper today than they were in the late '90s.
To demonstrate this, let's use a stock-value standard that nearly all investors agree on - the price/earnings (P/E) ratio. By that standard, tech stocks today are 81.7% cheaper than they were in the late '90s.
At the height of the dot-com rally, Nasdaq stocks traded at 175 times earnings. Today, that figure stands as 32 - making today's stocks five times cheaper than they were then.
When we take inflation into account, the Nasdaq is well below its previous high, Birinyi says. In 2000, the index would have to hit 6908 to have the same value as back then, for an additional rally of 38%.
In other words, tech stocks are nowhere near overheated.
And that means you still have plenty of ways to profit...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.